Biogen PE Ratio 2010-2022 | BIIB

Current and historical p/e ratio for Biogen (BIIB) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Biogen PE ratio as of May 23, 2022 is 11.44.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Biogen PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-23 199.40 20.41
2022-03-31 210.60 $9.77 21.56
2021-12-31 239.92 $10.40 23.07
2021-09-30 282.99 $10.22 27.69
2021-06-30 346.27 $12.46 27.79
2021-03-31 279.75 $19.06 14.68
2020-12-31 244.86 $24.45 10.01
2020-09-30 283.68 $30.21 9.39
2020-06-30 267.55 $34.14 7.84
2020-03-31 316.38 $32.40 9.76
2019-12-31 296.73 $31.47 9.43
2019-09-30 232.82 $28.12 8.28
2019-06-30 233.87 $26.88 8.70
2019-03-31 236.38 $23.21 10.18
2018-12-31 300.92 $21.60 13.93
2018-09-30 353.31 $15.47 22.84
2018-06-30 290.24 $14.11 20.57
2018-03-31 273.82 $14.00 19.56
2017-12-31 318.57 $11.92 26.73
2017-09-30 313.12 $16.31 19.20
2017-06-30 271.36 $15.23 17.82
2017-03-31 273.42 $15.95 17.14
2016-12-31 261.39 $16.92 15.45
2016-09-30 288.53 $17.70 16.30
2016-06-30 222.89 $17.14 13.00
2016-03-31 239.95 $16.28 14.74
2015-12-31 282.37 $15.34 18.41
2015-09-30 268.35 $15.31 17.53
2015-06-30 372.33 $14.78 25.19
2015-03-31 389.19 $13.86 28.08
2014-12-31 312.88 $12.39 25.25
2014-09-30 304.92 $10.57 28.85
2014-06-30 290.63 $9.00 32.29
2014-03-31 281.93 $8.05 35.02
2013-12-31 257.69 $7.82 32.95
2013-09-30 221.92 $7.13 31.12
2013-06-30 198.36 $6.75 29.39
2013-03-31 177.54 $6.30 28.18
2012-12-31 134.91 $5.76 23.42
2012-09-30 137.53 $5.75 23.92
2012-06-30 133.08 $5.51 24.15
2012-03-31 116.14 $5.08 22.86
2011-12-31 101.44 $5.03 20.17
2011-09-30 85.86 $4.80 17.89
2011-06-30 98.55 $4.42 22.30
2011-03-31 67.72 $4.36 15.53
2010-12-31 61.80 $3.96 15.61
2010-09-30 51.73 $4.03 12.84
2010-06-30 43.74 $3.93 11.13
2010-03-31 52.90 $3.30 16.03
2009-12-31 49.31 $3.34 14.76
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $29.239B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00